Enrollment underway in study of Mesoblast’s remestemcel-L in COVID-19

Mesoblast Limited (NASDAQ:MESO) announces the start of enrollment in a Phase 2/3 clinical trial evaluating allogeneic mesenchymal stem cell candidate remestemcel-L in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome.

Enrollment of up to 300 ventilator-dependent patients should wind up in three-to-four months. The primary endpoint is all-cause mortality within 30 days of randomization. A key secondary endpoint is the number of days off mechanical ventilator support.

https://seekingalpha.com/news/3566832-enrollment-underway-in-study-of-mesoblasts-remestemcel-l-in-covidminus-19